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IMPACT OF AGE, GENDER,AND OUT-OF-
POCKET COSTS ON THE TIME TO
DISCONTINUATION OF ORAL ANTI-DIABETIC
AGENTS AMONG PATIENTS WITH TYPE 
2 DIABETES
Raut M, Gause D, Law AW, Sung J
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVE: This study investigated the effect of age,
gender, and out-of-pocket expenditures on medication use
and the time to discontinuation among patients with Type
2 diabetes (T2D). METHODS: Patients’ pharmacy and
medical data were obtained from a proprietary claims
database. T2D patients, 18 years and above, on oral anti-
diabetic drugs, who received beneﬁts from managed care
organizations in the year 2000 were identiﬁed. The effects
of age, gender, and co-payment on the time to medication
discontinuation were estimated. A medication was con-
sidered discontinued when the prescription was not
reﬁlled at the end of its day’s supply for an additional
50% of day’s supply. Co-payments within 1-week inter-
vals were analyzed in a time-dependent Cox regression
model to measure their impact on discontinuation.
RESULTS: Approximately 11,350 patients were identi-
ﬁed with T2D. The median co-payment per prescription
was $8.30. The time-dependent Cox regression model
showed that the risk of medication discontinuation was
8% higher for every $5 increase in co-payment [Hazard’s
ratio = 1.015]. Females had a 6% higher risk to discon-
tinuation than males (p = .04). Patients age 62 and over
have a 67% higher risk of discontinuing their medication
than patients under 61 years (p < .01). CONCLUSIONS:
Out-of-pocket prescription medication costs maybe a
potential barrier to medication persistency. Co-payment,
in addition to age and gender, signiﬁcantly impacted the
prescription discontinuation. Lack of routine and timely
care has been documented to result in a consequent trans-
fer of these costs for severe health episodes to payers. Poli-
cies intended to reduce patient non-compliance should be
supported by managed care organizations.
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A METHODOLOGY TO IDENTIFY 
HIGH-RISK PATIENTS WITH DIABETES 
IN THE CALIFORNIA MEDICAID 
POPULATION (MEDI-CAL)
Chaikledkaew U1,Wu EQ2, Johnson KA1
1University of Southern California, Los Angeles, CA, USA;
2Analysis Group/Economics, Boston, MA, USA
OBJECTIVES: The purpose of this research is to develop
three econometric models [i.e., cost model (model #1); the
occurrence of hospitalization or ER event model (model
#2); time to hospitalization or ER event model (model
#3)] that can be used to identify high-risk patients and to
evaluate whether risk models are valid based on claims
data from the California Medicaid (MediCal) diabetic
patients. METHODS: A retrospective study was con-
ducted by using claims data from January 1995 to
December 2000. Dependent variables were total health-
care cost, the occurrence of event, and time to event.
Event included hospitalization or ER visits. Historical
data including demographic factors, healthcare cost and
utilization, type of drugs, increasing dose, adding drugs,
and changing drugs, follow-up services based on diabetic
guidelines (e.g., ofﬁce visit, lab tests, and self glucose
monitoring), medication compliance, complications, and
comorbidity were used as independent variables. The gen-
eralized estimating equation and the ﬁxed effect partial
likelihood methods were used in a longitudinal data set
and a cross-sectional data set with repeatable events,
respectively. The split sample validation method was
applied to validate the models. RESULTS: The results
show that if high-risk patients were identiﬁed by high
healthcare costs, model #1 was the most appropriate to
use since it yielded the highest percentage of correct pre-
dictions. Likewise, if high-risk patients were deﬁned as
patient who had the occurrence of hospitalization or ER
event, model #2 was the most suitable to apply. Similarly,
if high-risk patients were indicated by shorter time to hos-
pitalization or ER event, model #3 was the most proper
to utilize. Moreover, three models were valid. CON-
CLUSIONS: The choice of method depends on how 
high-risk is deﬁned by researchers or policy makers. Iden-
tiﬁcation of high-risk patients with diabetes could mean
healthcare providers and health plans could intervene to
improve patient management.
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DETERMINATION OF ASSOCIATION BETWEEN
DRUG COSTS AND MEDICAL COSTS IN
PATIENTS WITH TYPE 1 DIABETES
Shah S1, Siganga W2, Huang B2, Holiday-Goodman M2
1University of Texas at Austin, Austin,TX, USA; 2The
University of Toledo,Toledo, OH, USA
OBJECTIVES: Proper management of type 1 diabetes
with drugs may reduce medical spending affecting the
overall healthcare expenditures. The objectives of this
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study were 1) to determine whether there was an associ-
ation between drug costs and medical costs for type 1 dia-
betes patients and, 2) to develop a regression model that
predicts medical costs from drug costs. METHODS: The
records of 315 patients enrolled in a large mid-western
health care plan were reviewed for a 1-year period. The
drug costs included insulin costs and oral diabetes drug
costs. The medical costs included all paid services for
primary and secondary diagnosis of type 1 diabetes iden-
tiﬁed by ICD-9-CM codes. The data were analyzed using
SPSS 10.0. The association between drug and medical
costs was determined using Pearson correlation. The 
signiﬁcance level was set at the 95% conﬁdence interval.
Linear regression analysis was conducted to predict
medical costs from drug costs. The dependent variable
was the logarithm of medical costs. The independent 
variables were drug costs, length of service, additional
therapy, age and gender. RESULTS: There was a statisti-
cally signiﬁcant inverse correlation between drug costs
and medical costs (r = -0.229, CI: -0.33 - -0.13). In 
the regression model the following independent variables
were determined to be predictors of medical costs: drug
costs (b = 0.00, CI: -0.003 - -0.002), additional therapy
(b = -0.362, CI: -0.51 - -0.21) and length of service 
(b = 0.002, CI: 0.001 - 0.002). Age and gender were not
found to be signiﬁcant predictors of medical costs. 
CONCLUSIONS: The inverse correlation implies that if
type 1 diabetes is managed appropriately with drugs, 
the medical costs may be reduced. This may reduce the
overall health care expenditures. The regression model
also showed that as drug costs increased medical costs
decreased. The regression model can be used to predict
the future medical costs if the drug costs are known.
DIABETES—Economic Outcomes
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A COMPARISON OF TWO METHODS 
FOR ESTIMATING HEALTH CARE COSTS 
OF DIABETES
Gause D1, Law AW2, Singhal PK3
1Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA; 2Duke Clinical Research Institute, Durham, NC, USA;
3University of Maryland, Baltimore, MD, USA
Cost of illness estimates for chronic diseases can be under-
estimated if only costs related to diagnosis and treatment
of that disease are measured. This underestimation results
from overlooking costs associated with secondary conse-
quences of the disease such as complications and co-
morbid conditions associated with the disease.
OBJECTIVE: Two methods for estimating medical care
costs of diabetes were compared: an “attributable”
method” and a “case-control” method. METHODS: The
study population was all diabetic patients in the 1999
Medical Expenditure Panel Survey, a nationally represen-
tative series of probability surveys on the use and cost of
medical care in the United States. “Attributable” costs
were estimated by summing costs speciﬁcally associated
with diabetes. “Case-control” costs were estimated by
subtracting costs between diabetic cases and non-diabetic
controls which were matched on age, gender, race, and
number of comorbid conditions not related to diabetes.
Costs were summarized for pharmacy, hospital inpatient,
outpatient, and emergency room care and reported in
1999 dollars. RESULTS: The total cost of illness was
$3046 per patient using case-control method compared
to $1151 per patient using the attributable method. The
case-control method found costs to be higher for all cat-
egories of care, with the largest being hospital inpatient
costs. Cost differences were statistically signiﬁcant for 
all categories except for emergency room care. CON-
CLUSIONS: Diabetic “attributed” costs accounted for
only 39% of the total difference in health care costs
between diabetics and matched controls. Patients with
diabetes use more medical services than controls, but a
large portion of this care is not speciﬁcally attributed to
diabetes.
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USING LINEAR REGRESSION TO APPROXIMATE
RESULTS OF DECISION ANALYSIS: AN
APPLICATION TO A COST COMPARISON
ACROSS THREE FIRST-LINE DRUG STRATEGIES
IN TYPE 2 DIABETES
Botteman MF, Gao X, Stephens JM
Abt Associates Clinical Trials, Bethesda, MD, USA
OBJECTIVES: Few studies have compared the short-term
costs to achieve recommended glycemic goals in Type-2
diabetes. We developed a decision analysis to project costs
of treating patients to glycemic goals from a managed
care perspective and evaluated feasibility of summarizing
this model in an aggregate linear regression (LR) form.
METHODS: A literature-based decision model simulated
the 3-year treatment costs (medical, pharmacy, adverse
events) to achieve an HbA1c < 7% for three cohorts of
patients newly diagnosed with Type-2 diabetes and failing
lifestyle changes. Each cohort was assigned to a different
ﬁrst-line therapy: glipizide GITS, generic metformin, or
rosiglitazone. Add-on treatments occurred as necessary to
achieve glycemic control. To summarize the model in a
LR form, we ﬁrst conducted Monte Carlo simulations
(MCS) of the model for each therapy. The costs (depen-
dent variables) estimated via 1000 MCS runs were then
summarized through OLS regressions, using the most sen-
sitive and/or relevant variables from the decision model
as predictors. We then compared the results generated via
each method. RESULTS: The projected cost differences
between agents with the decision analysis and the aggre-
gate LR form were identical: -$558 (glipizide GITS vs.
metformin), -$1557 (glipizide GITS vs. rosiglitazone),
and -$998 (metformin vs. rosiglitazone). The R2 of 
the LR ranged between .49 and .53. Both methods led 
to identical conclusions regarding which agent was
least/most expensive in >97% of cases. The accordance
